Second Primary Cancer Risks After Breast Cancer in and Pathogenic Variant Carriers.

Purpose

Second primary cancer (SPC) risks after breast cancer (BC) in pathogenic variant (PV) carriers are uncertain. We estimated relative and absolute risks using a novel linkage of genetic testing data to population-scale National Disease Registration Service and Hospital Episode Statistics electronic health records.

Methods

We followed 25,811 females and 480 males diagnosed with BC and tested for germline PVs in NHS Clinical Genetics centers in England between 1995 and 2019 until SPC diagnosis, death, migration, contralateral breast/ovarian surgery plus 1 year, or the 31st of December 2020. We estimated standardized incidence ratios (SIRs) using English population incidences, hazard ratios (HRs) comparing carriers to noncarriers using Cox regression, and Kaplan-Meier 10-year cumulative risks.

Results

There were 1,840 and 1,750 female PV carriers. Compared with population incidences, carriers had elevated contralateral BC (CBC; SIR, 15.6 [95% CI, 11.8 to 20.2]), ovarian (SIR, 44.0 [95% CI, 31.4 to 59.9]), combined nonbreast/ovarian (SIR, 2.18 [95% CI, 1.59 to 2.92]), colorectal (SIR, 4.80 [95% CI, 2.62 to 8.05]), and endometrial (SIR, 2.92 [95% CI, 1.07 to 6.35]) SPC risks. carriers had elevated CBC (SIR, 7.70 [95% CI, 5.45 to 10.6]), ovarian (SIR, 16.8 [95% CI, 10.3 to 26.0]), pancreatic (SIR, 5.42 [95% CI, 2.09 to 12.5]), and combined nonbreast/ovarian (SIR, 1.68 [95% CI, 1.24 to 2.23]) SPC risks. Compared with females without PVs on testing, carriers had elevated CBC (HR, 3.60 [95% CI, 2.65 to 4.90]), ovarian (HR, 33.0 [95% CI, 19.1 to 57.1]), combined nonbreast/ovarian (HR, 1.45 [95% CI, 1.05 to 2.01]), and colorectal (HR, 2.93 [95% CI, 1.53 to 5.62]) SPC risks. carriers had elevated CBC (HR, 2.40 [95% CI, 1.70 to 3.40]), ovarian (HR, 12.0 [95% CI, 6.70 to 21.5]), and pancreatic (HR, 3.56 [95% CI, 1.34 to 9.48]) SPC risks. Ten-year cumulative CBC, ovarian, and combined nonbreast/ovarian cancer risks were 16%/6.3%/7.8% ( carriers), 12%/3.0%/6.2% ( carriers), and 3.6%/0.4%/4.9% (noncarriers). Male carriers had higher CBC (HR, 13.1 [95% CI, 1.19 to 146]) and prostate (HR, 5.61 [95% CI, 1.96 to 16.0]) SPC risks than noncarriers.

Conclusion

Survivors of BC carrying and PVs are at high SPC risk. They may benefit from enhanced surveillance and risk-reduction measures.

References:

• Breast Cancer Association Consortium. Dorling L, Carvalho S, et al. Breast cancer risk genes—Association analysis in more than 113,000 women. N Engl J Med. 2021;384:428–439. doi: 10.1056/NEJMoa1913948.
• Lau-Min KS, McCarthy AM, Nathanson KL, et al. Nationwide trends and determinants of germline BRCA1/2 testing in patients with breast and ovarian cancer. J Natl Compr Canc Netw. 2023;21:351–358.:e4. doi: 10.6004/jnccn.2022.7257.
• Morra A, Mavaddat N, Muranen TA, et al. The impact of coding germline variants on contralateral breast cancer risk and survival. Am J Hum Genet. 2023;110:475–486. doi: 10.1016/j.ajhg.2023.02.003.
• Marcheselli R, Marcheselli L, Cortesi L, et al. Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study. J Breast Cancer. 2015;18:378–385. doi: 10.4048/jbc.2015.18.4.378.
• Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96:222–226.